Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Butylphthalide-telmisartan heterocomplex and preparation method and application thereof

A kind of technology of telmisartan and compound, applied in butylphthalide-telmisartan hybrid compound and its preparation and use field

Active Publication Date: 2017-06-06
GUANGDONG LONGFU MEDICINE CO LTD
View PDF3 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, when PHPB is taken orally, the bioavailability of NBP converted into NBP in the body is nearly doubled compared with direct oral NBP, which completely overcomes the disadvantage of poor water solubility of NBP

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Butylphthalide-telmisartan heterocomplex and preparation method and application thereof
  • Butylphthalide-telmisartan heterocomplex and preparation method and application thereof
  • Butylphthalide-telmisartan heterocomplex and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0103] Synthesis of 2-(1-hydroxy-n-pentyl)benzoic acid (III):

[0104] Dissolve 1.24g (6.5mmol) NBP in 10mL of methanol, add 10mL of 2M NaOH solution, reflux and stir for 0.5h, distill methanol off under reduced pressure, add 10mL of distilled water to dilute, cool to -5°C, and use 5% dilute hydrochloric acid under vigorous stirring Acidify to pH 2-3, extract with ether (15mL×3), and directly put into the next reaction without any purification.

Embodiment 2

[0106] Synthesis of 2-(1-acetyl n-pentyl)benzoic acid:

[0107] Dilute the ether solution containing III above with 200mL of dichloromethane, add 2.7mL (19.6mmol) of triethylamine and 0.5g of DMAP respectively, add 1.4mL (19.6mmol) of acetyl chloride dropwise at -10°C, and drop to -10 Stir at ℃ for 5h, add 10mL of water, stir at room temperature for 0.5h, separate the organic layer, Na 2 SO 4 Dry, filter, and concentrate to obtain a waxy solid, which is recrystallized from n-hexane to obtain 1.06 g of white needle-like crystals, with a yield of 65%. mp 65-66℃.MS(ESI):m / z 249.1[M-H]-. 1 H NMR (300MHz, CDCl 3 ):δ0.93(t,3H,CH 3 ,J=8.5Hz),1.37–1.42(m,4H,2×CH 2 ), 1.88–1.91 (m,2H,CH 2 ),2.13–2.33(m,3H,COCH 3 ),6.61–6.72(m,1H,OCHCH 2 ),7.37–7.40(m,1H,ArH),7.56–7.62(m,2H,ArH),8.05(d,1H,ArH,J=8.1Hz),10.98(brs,1H,COOH). 13 C NMR (75MHz, CDCl 3 ): δ172.0, 166.5, 140.8, 133.1, 130.3, 130.0, 127.1, 125.7, 74.8, 41.0, 36.3, 27.8, 22.4, 13.8.

Embodiment 3

[0109] A representative intermediate V for the coupling of diols based on 2-(1-acetyl-n-pentyl)benzoic acid 1 Synthesis:

[0110] Dissolve 2-(1-acetyl n-pentyl)benzoic acid (2.50g, 10.0mmol) in anhydrous dichloromethane (50mL), add EDAC (2.29g, 12.0mmol) and a catalytic amount of DMAP, stir at room temperature for 0.5 h, then added ethylene glycol (0.62g, 10.0mmol), stirred at room temperature for 5h, filtered, concentrated under reduced pressure, and obtained oily substance 1.71 through column chromatography [petroleum ether: ethyl acetate (v:v) = 30:1] g, yield 58%. MS(ESI):m / z 317.1[M+Na] + . 1 H NMR (300MHz, CDCl 3 ):δ0.807(t,3H,CH 3 ,J=7.0Hz), 1.181-1.356(m, 4H, 2×CH 2 ),1.730-1.777(m,2H,CH 2 ),1.965(s,3H,COCH 3 ),3.823-3.862(m,2H,CH 2 ),4.269-4.474(m,2H,CH 2 ), 5.206(s, 1H, OH), 6.452(t, 1H, COOCH, J=6.7Hz), 7.197-7.265(m, 1H, ArH), 7.441-7.444(m, 2H, ArH), 7.750-7.777 (m,1H,ArH). 13 CNMR (75MHz, CDCl 3 ): δ170.90, 167.51, 142.37, 132.15, 129.94, 129.34, 127...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the fields of pharmaceutical chemistry and pharmaceutical therapeutics, and more particularly to an optically active ring-opening butylphthalide-telmisartan heterocomplex or a pharmaceutically acceptable salt or ester thereof, preparation methods thereof, pharmaceutical compositions containing the compounds, and pharmaceutical application of the pharmaceutical compositions, particularly application in prevention and treatment of neuroinflammation-related diseases, including ischemic stroke, alzheimer's disease, brain trauma, Parkinson's disease, multiple sclerosis and depression.

Description

technical field [0001] The present invention relates to a butylphthalide-telmisartan hybrid, in particular to an optically active ring-opening butylphthalide-telmisartan hybrid or a pharmaceutically acceptable salt or ester thereof. Preparation methods, pharmaceutical compositions containing these compounds and their medical use, especially in the prevention and treatment of diseases related to neuroinflammation, including ischemic stroke, Alzheimer's disease, traumatic brain injury, Parkinson's disease , multiple sclerosis, depression and other aspects of the application, belongs to the field of pharmaceutical technology. Background technique [0002] Microglia in the central nervous system (CNS) play a key role in mediating various immune-related functional diseases, which are divided into pro-inflammatory type (M1 classic type) and anti-inflammatory type (M2 alternative activated type). M1 microglia highly express oxidative metabolites (such as superoxide and nitric oxid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D235/18A61K31/4184A61P9/10A61P25/00A61P29/00A61P25/28A61P25/16A61P25/24
CPCC07D235/18A61P9/10A61P25/00A61P29/00A61P25/16C07D403/04C07D257/04C07D403/10
Inventor 黄张建庞涛黄云张陆勇王云杰张奕华
Owner GUANGDONG LONGFU MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com